Abstract
The metabolism of dapsone was studied in ten patients with proven dermatitis herpetiformis. Seven of the patients, who were slow acetylators of sulphadimidine, also acetylated dapsone slowly. Three of the patients were rapid acetylators of both drugs. The control of symptoms did not seem to be related to the plasma concentrations of dapsone or of its metabolite monoacetyldapsone. Haemato-logical side effects, however, were related to plasma dapsone concentrations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
